2-Oxoindole 14-3-3 Modulators for Antitumor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents targeting 14-3-3 proteins, which are implicated in various cancers and neurodegenerative diseases, with no clinical agents developed despite their potential as therapeutic targets.
Innovation Solution
Development of 2-oxoindole derivatives that act as 14-3-3 protein modulators, specifically compounds of Formula (I) and (II), which are capable of affecting human cancer growth in both in vitro and in vivo models, particularly effective against lymphoma, chronic lymphocytic leukemia, Ewing sarcoma, colon cancer, melanoma, and anaplastic thyroid cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 14-3-3 proteins are targeted as therapeutic agents, then antitumor activity is improved, but no clinical agents have been developed despite multiple drug discovery campaigns
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of 2-oxoindole derivatives to optimize binding affinity and selectivity for 14-3-3 proteins. Specific modifications include varying substituents at positions R1-R6 to enhance pharmacological properties, thereby resolving the contradiction between achieving reliable antitumor activity and progressing drug development.
Solution Approach 2:
The patent uses the R18 peptide as a template and creates novel 2-oxoindole derivative compounds that replicate and improve upon its binding mechanism to 14-3-3 proteins. These compounds copy the successful binding approach but with enhanced pharmacological properties, enabling clinical development progress.
2Adaptability or versatility
If 2-oxoindole derivatives are synthesized and tested, then new 14-3-3 protein modulators are identified, but the complexity of compound synthesis and testing increases
Solution Approach 1:
The patent segments the 2-oxoindole core structure with specific substituent groups (R1-R6) that can be independently optimized. This segmentation allows systematic exploration of chemical space to identify active modulators while managing synthesis complexity through modular assembly of functional units.
Solution Approach 2:
The patent develops a universal 2-oxoindole derivative framework that can be adapted to target different 14-3-3 protein isoforms and interact with various client proteins. This multi-functional platform reduces the need for completely new compound synthesis for each target, thereby managing complexity while maintaining versatility.
3Reliability
If existing antitumor agents are combined with 2-oxoindole derivatives, then synergistic effects are achieved, but the complexity of combination therapy increases
Solution Approach 1:
The patent identifies 14-3-3 proteins as intermediary targets that mediate between multiple signaling pathways and cancer cell survival. By targeting this central hub with 2-oxoindole derivatives, the compounds can synergize with existing antitumor agents through a common mechanism, simplifying combination therapy development compared to multi-target approaches.
Data Source
AI summary
The invention relates to a 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are, independently from each other, hydrogen, 1H-imidazolyl, thienyl and 1-methyl-1H-imidazolyl, 2-methyl-1H-imidazolyl, 2-aminopyridinyl, 1H-pyrazolyl, with the proviso that one of R1 and R2 is hydrogen; or R1 and R2 together form 9H-fluorene R3 is hydrogen, (C1-C3)alkyl, halogen or NO2; for use as a 14-3-3 protein modulator of a tumor selected from the group consisting of a lymphoma, chronic lymphocytic leukaemia (CLL), Ewing sarcoma, colon cancer, melanoma and anaplastic thyroid cancer (ATC). The invention relates also new 2-oxoindole compound of Formula (I) or a pharmaceutically acceptable salt thereof.